Pyridinoylpiperidines as 5-HT1F agonists

US7423050B2 · kind B2 · utility

Assignee

• ELI LILLY AND COMPANY · US

Inventors

• Michael Philip Cohen · Indianapolis, US
• Daniel Timothy Kohlman · Camby, US
• Sidney Liang · Bethany, US
• Vincent Mancuso · Thy-le-Château, BE
• Yao-Chang Xu · Indianapolis, US
• Bai-Ping Ying · Greenville, US
• DeAnna Piatt Zacherl · Noblesville, US
• Deyi Zhang · Carmel, US
• Frantz Victor · Indianapolis, US

Key dates

• Filing date: Mar 27, 2003
• Grant date: Sep 9, 2008
• Expiry date: Jul 4, 2024

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02P20/55
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to compounds of formula I:or pharmaceutically acceptable acid addition salts thereof, where;R1 is C1-C6 alkyl, substituted C1-C6 alkyl, C3-C7 cycloalkyl, substituted C3-C7 cycloalkyl, C3-C7 cycloalkyl-C1-C3 alkyl, substituted C3-C7 cycloalkyl-C1-C3 alkyl, phenyl, substituted phenyl, heterocycle, or substituted heterocycle;R2 is hydrogen, C1-C3 alkyl, C3-C6 cycloalkyl-C1-C3 alkyl, or a group of formula IIR3 is hydrogen or C1-C3 alkyl;R4 is hydrogen, halo, or C1-C3 alkyl;R5 is hydrogen or C1-C3 alkyl;R6 is hydrogen or C1-C6 alkyl; andn is an integer from 1 to 6 inclusively.The compounds of the present invention are useful for activating 5-HT1F receptors, inhibiting neuronal protein extravasation, and for the treatment or prevention of migraine in a mammal. The present invention also relates to a process for the synthesis of intermediates in the synthesis of compounds of Formula I.